In countries in Central and Eastern Europe (CEE), significant delays in patient access to innovative oncology treatments have been previously described.21,22,23,24 In an attempt to avoid such delays with ADCs in HER2-low BC, an expert meeting was held to identify the challenges and local unmet needs, and to find solutions to optimize access to diagnostics and adequate treatment of HER2-low metastatic BC (mBC) for patients from CEE. Here, ERBB2 is linked to breast cancer.